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KidneyDiabetic nephropathy (DN) is the most common cause of end-stage renal disease and identiﬁcation of new ther-
apeutic targets is needed. Nicotinamide phosphoribosyltransferase (NAMPT) is both an extracellular and intra-
cellular protein. Circulating NAMPT is increased in diabetics and in chronic kidney disease patients. The role of
NAMPT in renal cell biology is poorly understood. NAMPT mRNA and protein were increased in the kidneys of
rats with streptozotocin-induced diabetes. Immunohistochemistry localized NAMPT to glomerular and tubular
cells in diabetic rats. The inﬂammatory cytokine TNFα increased NAMPT mRNA, protein and NAD production
in cultured kidney human tubular cells. Exogenous NAMPT increased the mRNA expression of chemokines
MCP-1 and RANTES. The NAMPT enzymatic activity inhibitor FK866 prevented these effects. By contrast,
FK866 boosted TNFα-induced expression of MCP-1 and RANTES mRNA and endogenous NAMPT targeting by
siRNA also had a proinﬂammatory effect. Furthermore, FK866 promoted tubular cell apoptosis in an inﬂammato-
ry milieu containing the cytokines TNFα/IFNγ. In an inﬂammatory environment FK866 promoted tubular cell
expression of the lethal cytokine TRAIL. These data are consistent with a role of endogenous NAMPT activity as
an adaptive, protective response to an inﬂammatory milieu that differs from the proinﬂammatory activity of ex-
ogenous NAMPT. Thus, disruption of endogenous NAMPT function in stressed cells promotes tubular cell death
and chemokine expression. This informationmay be relevant for the design of novel therapeutic strategies in DN.
© 2013 Published by Elsevier B.V.1. Introduction
Diabetic end-organ damage contributes to at least 233,000 yearly
deaths in the US alone. Diabetic nephropathy (DN) is themost common
cause of end-stage renal disease [1,2]. Failure of current therapeutic
approaches to successfully prevent progression of DN in a sizable pro-
portion of patients must be ascribed to an incomplete understanding
of themolecular pathways contributing to DN progression. The diabetic
microenvironment induces apoptosis in various organs and apoptosis is
believed to contribute to the gradual loss of renal function and renal cell
mass in DN [3–5]. Renal tubular epithelial, endothelial and interstitial
cell apoptosis is observed in DN [6–8]. DN is also characterized by an
inﬂammatory response [9,10]. Both apoptosis and inﬂammation may
be interrelated. Thus several cytokines, such as TNFα and TRAIL regulateación Jiménez Díaz, Av Reyes
fax: +34 91 544 26 36.
vier B.V.both apoptosis and inﬂammation in kidney cells in a diabetic milieu
[10].
Nicotinamide phosphoribosyltransferase (NAMPT)/visfatin/pre-
B-cell colony-enhancing factor (PBEF) was originally identiﬁed as a
secreted growth factor for early B cells [11]. Visfatin was described
as an adipokine with insulin mimetic action that improved glucose
tolerance [12]. However, the original description of visfatin activity
was retracted because of the irreproducibility of the results.
NAMPT was described as an intracellular enzyme in the mammalian
salvage pathway of nicotinamide adenine dinucleotide (NAD)+ that
catalyzes the synthesis of nicotinamide mononucleotide (NMN)
from nicotinamide and phosphoribosylpyrophosphate (PRPP) [13].
NAMPT is now the ofﬁcial name for gene and protein approved by
the HUGO Gene Nomenclature Committee [14,15]. The NAMPT
gene encodes a 491 amino acid protein with a predicted molecular
weight of 52 kD. The crystal structure of NAMPT suggested a homo-
dimeric enzyme [15]. Additional non-enzymatic NAMPT functions
include proinﬂammatory effects on leukocytes and tumor cells
[16,17], pro-angiogenic effects on endothelial cells [18] and prolifer-
ative actions on vascular smooth muscle cells [19]. FK866 is now
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reduces NAD+ levels and promotes apoptosis of tumor cells [15,20].
In this regard, studies are underway to validate NAMPT as a target for
the development of new anticancer agents.
There is scarce information on NAMPT and kidney disease. High
glucose increases NAMPT expression in cultured rat mesangial cells,
and murine podocytes and tubular cells [21,22]. Exogenous extracellu-
lar NAMPT increased the synthesis of pro-ﬁbrotic molecules in these
renal cell types through a mechanism requiring actin polymerization
and/or glucose uptake since it was inhibited by the actin polymerization
inhibitor cytochalasin B. In a genetic rat model of type 2 diabetes,
plasma NAMPT levels were increased in the early stages of DN and
positively correlated with microalbuminuria. Glomerular and tubular
cell NAMPT was increased in this model of DN. As a whole, these data
suggested a deleterious action of NAMPT on renal cells that might
contribute to the pathogenesis of DN [21,22]. Mesangial cell NAMPT
enzymatic activity may be inhibited by FK866 [21]. However the role
of NAMPT enzymatic activity in renal cells beyond regulation of glucose
uptake was not addressed.
We now aimed at unraveling the role in kidney cells of the increased
endogenous NAMPT observed during kidney injury. We describe in-
creased local kidney NAMPT in a type 1 diabetes model and in cultured
tubular cells exposed to TNFα. We also describe the interplay between
endogenous NAMPT and inﬂammatory cytokines in the regulation of
chemokine expression and cell death. The data suggest a cytoprotective,
anti-inﬂammatory role of inﬂammation-induced endogenous NAMPT
in tubular cells.
2. Materials and methods
2.1. Animal model
Diabeteswas induced in six 6-week-old rats (WKY, Criffa, Barcelona,
Spain) by a single intraperitoneal injection of 50 mg/kg streptozotocin
(Sigma, St. Louis, MO, USA) in 0.01 M citrate buffer pH 4.5. Six control
rats received the vehicle. Rats were sacriﬁced at 6 weeks following
induction of diabetes. Kidneys were perfused in situ with cold saline
before removal. One kidney was ﬁxed in buffered formalin, embedded
in parafﬁn and used for immunohistochemistry, and the other kidney
was snap-frozen in liquid nitrogen for RNA and protein studies of
renal cortexes [23]. Insulin (Insulatard NPH, Novo Nordisk, Denmark)
was administered at a dose of 1–4 IU s.c. weekly to prevent death
from 7 days after administration of streptozotocin, once all animals
had blood glucose levels N400 mg/dL. Twenty-four hour albuminuria
was assessed by ELISA (Celltrend, Luckenwalde, Germany). Table 1
presents animal model data. All studies were performed in accordance
with the European Union normative.
2.2. Immunohistochemistry
Immunohistochemistry was carried out in 5 μm thick parafﬁn-
embedded rat kidney sections. The primary antibody was a mouse
monoclonal anti-NAMPT (1:200, Enzo life science). Sections were
counterstained with Carazzi's hematoxylin. Negative controls included
incubation with a non-speciﬁc immunoglobulin of the same isotype as
the primary antibody. Image quantiﬁcation was carried out withTable 1
Rat weight gain and laboratory data at sacriﬁce.
Weight
gain (%)
Systolic BP
(mm Hg)
Glycemia
(mg/dL)
Urinary albumin
(mg/24 h)
Control 76 ± 18 112 ± 4 126 ± 2 0.44 ± 0.3
DN 61 ± 25 121 ± 5⁎ 383 ± 135⁎ 2.31 ± 0.4⁎
Mean ± SEM of 6 animals per group.
⁎ p b 0.05 vs control.ImageProPlus software (MediaCybernetics, Bethesda,MD) as previously
described [24]. This software allows selecting and calculating the
area of pixels with similar color. Results are shown as percentage of
positive stained area versus total area from 10 ﬁelds per kidney
(×200 magniﬁcation).
2.3. Cell culture
HK-2 human proximal tubular epithelial cells (ATCC, Rockville, MD)
were grown on RPMI 1640 (GIBCO, Grand Island, NY), 10% heat-
inactivated fetal bovine serum (FBS), 2 mM glutamine, 100 U/mL
penicillin, 100 μg/mL streptomycin, 5 μg/mL insulin, 5 μg/mL transfer-
rin, 5 ng/mL sodium selenite, and 5 ng/mL hydrocortisone in 5% CO2
at 37 °C as previously described [10]. For experiments cells were rested
in serum-free media for 24 h prior to the addition of stimuli and
throughout the experiment. To assess the effect of different concentra-
tions of glucose, cells were grown in DMEM 5 mM or 25 mM glucose
(Lonza) with the same additives [25].
2.4. Cell stimulation and NAMPT targeting
Exogenous extracellular NAMPT (eNAMPT) was purchased from
Peprotech (USA). The protein is produced in Escherichia coli. The purity
is N98%. Concentrations used (10–200 ng/mL range) are indicated in
the ﬁgure legends. Wild-type and NAMPT (R392A, S200D and H247E)
mutants (a kind gift from C. Wolberger) [26] were used at 100 ng/mL.
R392A retains 36% of the original enzymatic activity showed by
NAMPT, S200D 12% and H247E 8.50%. NAMPT siRNA (ID 10135;
Trilencer-27, SR306835, Origene). Cells were transfectedwith lipofecta-
mine. FK866 (1–10 nM; Axon 1279, AxonMedchem)was always added
90 min before other stimuli. 50 ng/mL of TNFα and 5 ng/mL of IFNγ
(Peprotech, UK) were used.
2.5. NAD/NADH assay
Total cell NAD was assayed by a commercial NAD/NADH quantiﬁca-
tion kit following manufacturer's instructions (Abcam, Cambridge, UK).
Brieﬂy, cells were washed in cold PBS and lysed. Fifty microliter cell
lysate was used for the kit protocol and for protein quantiﬁcation. All
results were corrected by the protein content of each sample.
2.6. Cell death and apoptosis
Apoptosiswas quantiﬁed by ﬂow cytometry of DNA content, as previ-
ously described [27]. Adherent cells were pooledwith spontaneously de-
tached cells and stained in 100 μg/mL propidium iodide, 0.05% NP-40,
and 10 μg/mL RNAse A in PBS at 4 °C for N1 h. This assay permeabilizes
the cells and allows entry of propidium iodide in all cells, dead and
alive. Nuclear fragmentation and the consequent reduction in DNA
amount (hypodiploid cells) is one of themain characteristics of apoptotic
cells. The percentage of apoptotic cells with decreased DNA content (A0)
was counted. Exposure to a lethal cytokine cocktail (50 ng/mL TNFα, and
5 ng/mL IFNγ, Peprotech, UK) present in the diabetic milieu for 24 hwas
used as a proinﬂammatory lethal stimulus [10]. Cytokine concentrations
were based on prior experience and dose-response studies from our lab
[28,29]. Cells were seeded at a density of 25,000/mL (12-well plates for
ﬂow cytometry and coverslips for cytoﬂuorescence) and grown for
24 h. Thereafter, they were rested in serum-free medium for 24 h and
stimuli were added to subconﬂuent cells. Cells were also seeded in
96-well plates, serum depleted for 24 h, stimulated and then assayed
for cell viability with the MTS–PMS assay (Promega).
2.7. Western blot
Protein extracts were isolated with lysis buffer and western blots
were performed as described previously [27]. Membranes were
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EnzoLife Science), which recognizes the intracellular and extracellular
forms of human NAMPT, anti-TRAIL (1:1,000, R&D systems), or mouse
anti-β Actinmonoclonal antibody (1:5000, Abcam) followed by incuba-
tion with horseradish peroxidase-conjugated secondary antibody
(1:2000, Amersham, Aylesbury, UK). Blots were developedwith the en-
hanced chemiluminescencemethod (ECL) following themanufacturer's
instructions (Amersham).
2.8. Reverse transcription and real time PCR
RNA was isolated using TRIzol reagent. Reverse transcription of
RNA and real time quantitative-PCR was performed as previouslyC)
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Fig. 1. KidneyNAMPT expression is increased in rats with type 1 diabetes. A)Whole kidney NAM
as loading control. B) Kidney NAMPT mRNA levels are signiﬁcantly increased in rat DN. Values
nohistochemistry. Representative images.Magniﬁcation 20× and detail. Neg. con.: negative con
trol. Mean + S.E.M. of 6 animals.described. Pre-developed TaqMan reagents were used for RANTES,
MCP-1 and IL-6 (Applied Biosystems, Darmstadt, Germany), and
normalized for 18S ribosomal RNA. Quantiﬁcation of templates and
relative expression for each gene were achieved following the
model R = 2e(−ΔΔCt). Serial dilutions of kidney or cellular cDNA
were included in all PCR runs and served as standard curve. All
measurements were performed in duplicate. Controls consisting of
bidistilled H2O were negative in all runs.
2.9. ELISA
The ELISA kit for MCP-1 (R&D, Minneapolis, MN; USA) was
carried out following manufacturer's instructions in HK2 cell culture0
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trol for the technique. D)NAMPT immunohistochemistry. Quantiﬁcation. *p b 0.05 vs con-
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by 540 nm wavelength.2.10. Statistical analysis
Results are expressed as mean ± S.E.M. of at least three indepen-
dent experiments. Signiﬁcance at the p b 0.05 level was assessed by
non-parametric Mann–Whitney test for two groups of data and
Kruskal–Wallis or one-way analysis (ANOVA) with a Bonferroni post
hoc correction for analysis of differences between three or more groups
by SPSS software (SPSS Inc., Chicago, IL).3. Results
3.1. Increased local kidney NAMPT in rat type I diabetes
Rats with streptozotocin-induced diabetes or non-diabetic vehicle-
injected controls were sacriﬁced at 6 weeks. At the time of sacriﬁce,
diabetic rats had developed albuminuria (Table 1). Whole kidney
NAMPT protein (Fig. 1A) and mRNA (Fig. 1B) were increased in the0
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3.2. TNFα increases NAMPT in cultured human tubular cells
We focused on tubular cells in search of factors potentially driving
NAMPT expression in DN. TNFα is a multifunctional cytokine involved
in DN progression [9,30]. TNFα increased NAMPT mRNA expression at
3 h in cultured human tubular epithelial cells. There was a non-
signiﬁcant trend towards increased NAMPT mRNA levels in cells
cultured with high glucose concentrations at 24 (Fig. 2A) and 48 h
(data not shown). Similar results were observed at the protein level.
High glucose tended to increase NAMPT while TNFα signiﬁcantly in-
creased cell-associated NAMPT expression after 48 h of stimulation
(Fig. 2B), while increased levels of soluble NAMPT in the culture medi-
um were already evident at 24 and 48 h following TNFα stimulation
(Supplementary Fig. 1). No differences in protein expression were
observed at 3 h (not shown). TNFα also increased NAD, suggesting an
increased NAMPT enzymatic activity after 24 h of stimulation, an effect
abrogated by the NAMPT enzymatic activity inhibitor FK866 (Fig. 2C).
However, we cannot exclude that TNFα modulates nicotinamideControl TNFα Control TNFα
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sible for NAD generation.
3.3. Exogenous NAMPT is proinﬂammatory in tubular cells
In order to assess the role of NAMPT in tubular cells we added exog-
enous NAMPT to the cells. Exogenous NAMPT did not modulate human
tubular cell viability (Fig. 3A), apoptosis (Fig. 3B) or proliferation
(Fig. 3C). However, NAMPT dose-dependently increased the mRNA
expression of the chemokine MCP-1 (Fig. 4A). This effect is similar to
that previously reported in murine tubular cells and podocytes and
human vascular smooth muscle cells [22,31].
3.4. Exogenous NAMPT proinﬂammatory activity depends on its
enzymatic activity
Previously described actions of exogenous NAMPT on kidney cells
were thought to be a cytokine-like activity dependent on its now
retracted insulin-mimetic properties promoting glucose entry into
the cells [21,32]. However, in cultured human tubular cells inhibition
of NAMPT enzymatic activity by FK866 decreased the proinﬂamma-
tory actions of exogenous NAMPT on the mRNA expression of the
chemokines MCP-1 (Fig. 4B) and RANTES (Fig. 4C). We conﬁrmed
the requirement for the enzymatic activity for the proinﬂammatory
effects using speciﬁc NAMPT mutants. Cells stimulated with NAMPT
mutated in the catalytic site failed to upregulate the mRNA expression
of MCP1, RANTES and IL-6 (Fig. 4D). These two sets of independent
experiments suggest dependence of the proinﬂammatory action of
exogenous NAMPT on its enzymatic activity.
3.5. Inhibition of endogenous NAMPT magniﬁes chemokine expression
Since cellular NAMPT was increased in tubular cells cultured in an
inﬂammatory milieu and in tubular cells in vivo, we next explored
whether endogenous NAMPT expressed in response to TNFα mightA)
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towards baseline at 24 h (Fig. 5A). When endogenous NAMPT activity
was inhibited by FK866, TNFα proinﬂammatory effects were prolonged
in time and increasedMCP-1mRNAwas still observed at 24 h (Fig. 5A).
Endogenous NAMPT inhibition also prolonged peak expression of
RANTES, a gene whose expression in response to TNFα increases later
and is more persistent than that of MCP-1 [24] (Fig. 5B). Endogenous
NAMPT inhibition of cytokine-induced chemokine expression was
conﬁrmed when assessing secreted MCP-1 by ELISA. TNFα increased
MCP-1 secretion in tubular epithelial cells, and this increment was
higher when endogenous NAMPT was inhibited (Fig. 5C). We next
studied the effect of knocking down NAMPT expression by siRNA.
siRNA-mediated knock-down of NAMPT resulted in increased RANTES
mRNA and a trend towards increasedMCP-1mRNA, both spontaneously
and in the presence of TNFα (Fig. 5D,E). Thus, endogenous renal tubular
cell NAMPT in response to TNFα appears to limit the proinﬂammatory
action of TNFα. Furthermore, the spontaneous proinﬂammatory action
of knocking down endogenous NAMPT suggests that part of the anti-
inﬂammatory action of endogenous NAMPT may be enzyme activity-
independent. In conclusion, under the conditions explored endogenous
and exogenous NAMPT have opposite effects on chemokine expression.3.6. Endogenous NAMPT may modulate cell death and tubular
cell proliferation
Since tubular cell apoptosis is a feature of DN [4], we next studied
the modulation of apoptosis by endogenous tubular cell NAMPT by
inhibiting its enzymatic activity. FK866 alone increased tubular cell pro-
liferation after 24 h (Fig. 6A), but did notmodify the apoptotic rate at 24
or 48 h in the absence of an inﬂammatory milieu (Fig. 6B). However, in
an inﬂammatory microenvironment composed of TNFα and IFNγ simi-
lar to what may be found in DN [9], the inhibition of endogenous
NAMPT increased the apoptotic rate at 48 h (Fig. 6C). Thus, the increaseB)
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antiapoptotic action.
3.7. Inhibition of endogenous NAMPT enhances TNFα/IFNγ-induced
expression of the lethal cytokine TRAIL
We next addressed the relationship between proinﬂammatory
cytokines, endogenous NAMPT and lethal cytokine expression. A
proinﬂammatory milieu composed of TNFα and IFNγ increased
expression of TRAIL, the most upregulated lethal cytokine in DN, as
previously observed by our group [10]. Inhibition of endogenous
NAMPT enzymatic activity by FK866 did not modulate TRAIL expres-
sion by itself, but increased cytokine-induced TRAIL upregulation
(Fig. 7). TRAIL had been previously shown to promote tubular cell
death in an inﬂammatory milieu [10].
4. Discussion
The main ﬁndings of our study are that NAMPT is upregulated by
inﬂammatory mediators in human tubular cells and that endogenous
NAMPT enzymatic activity plays a key role in protecting tubular cells
from adverse consequence of an inﬂammatory environment such as
cell death and a prolonged inﬂammatory response. This is consistent
with the hypothesis that upregulation of endogenous NAMPT during
kidney injury might be a compensatory protective mechanism that re-
quires NAMPT enzymatic activity to protect from apoptosis and quench
the inﬂammatory tubular cell response. This effect is in contrast to thepreviously described proinﬂammatory effect of exogenous NAMPT,
that we have also observed and determined to be dependent on
NAMPT enzymatic activity [31]. The involvement of the enzymatic ac-
tivity is in line with a prior report in mesangial cells, where exogenous
NAMPT actions on glucose transport were prevented by FK688 [21].
However, these observations differ from ﬁndings in other organs,
since in a lung carcinoma epithelial cell line NAMPT overexpression
increased expression of inﬂammatory cytokines via a nonenzymatic
mechanism [17]. Our experimental design differs from the latter in
that we assessed the role of endogenous NAMPT following stimulation
of its expression by a pathophysiologically relevant stimulus, as
opposed to the enforced genetic-mediated expression of the gene.
There are controversial results on NAMPT and diabetes, including
the retraction of the initial report of its insulin mimetic activity [12].
Mice lacking NAMPT develop impaired glucose tolerance and defective
insulin secretion, which are restored by administration of exogenous
NAMPT [33]. NAMPT-mediated NAD biosynthesis regulates glucose
homeostasis and maintenance of high circulating NMN levels by
NAMPT is critical for normalβ cell function [33]. However, NAMPT plas-
ma levels have been reported increased, unchanged or decreased in
diabetic patients [34–37] and are increased in CKD patients [38,39]. In
experimental diabetes, plasma and renal NAMPT were elevated in
type 2 diabetes rats with DN [22]. We have now conﬁrmed increased
tubular NAMPT in a type 1 diabetes DN model and provide evidence
for a role of locally synthesized NAMPT in tissue protection in the
presence of a cell environment that recapitulates the diabetic kidney
injury milieu. This protective action of endogenous NAMPT, in the
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mean + S.E.M. of 3 independent experiments. C) Secreted MCP-1 was measured by ELISA in HK2 cell supernatants. TNFα for 24 h increased MCP-1 release. Preincubation with the
NAMPT inhibitor FK866 resulted in a higher increase in MCP-1 secretion. *p b 0.05 vs. control, #p b 0.05 vs. TNFα. D, E) Tubular epithelial cells were transfected with scramble or
NAMPT siRNA for 24 h, and then 50 ng/mL TNFα was added for 24 h. MCP-1 (D) and RANTES (E) mRNA were assessed by real time RT-PCR. Results expressed as mean + S.E.M. of 3
independent experiments *p b 0.03 vs control.
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role described up to now for exogenously added or for the enforced
overexpression of NAMPT.
Once demonstrated increased NAMPT in diabetic kidneys, the next
step was to identify the factors responsible for this high expression.
High glucose concentrations upregulate NAMPT synthesis in rat
mesangial cells, murine podocytes and tubular cells [21,22]. We alsoobserved a trend toward increased NAMPT in human tubular cells ex-
posed to a high glucose concentration, although the effect was milder
than the one described in murine cells [22]. In contrast to the failure
of angiotensin II to upregulate NAMPT in rat and murine renal cells
[21,22], we now report that TNFαupregulates NAMPT in human tubular
cells. TNFα is upregulated in human and rat DN [9,30]. Cytokines also
upregulated expression of NAMPT in rheumatoid arthritis synovial
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Fig. 6. Inhibition of endogenous NAMPT enzymatic activity promotes tubular cell apoptosis in an inﬂammatory milieu. A) The NAMPT inhibitor FK866 increased the proliferation rate in
proximal tubular cells cultured in glucose 11 mM. B) However, FK866 alone did not inﬂuence apoptosis. Both processes were assessed by ﬂow cytometry analysis of DNA content.
*p b 0.05 vs control. Mean + S.E.M. of 3 independent experiments. C) The pro-apoptotic effect of TNFα/IFNγ (50 ng/mL and 5 ng/mL) in a high glucose milieu (25 mM) was increased
when NAMPT enzymatic activity was inhibited with 10 nM FK866 for 48 h. *p b 0.05 vs TNFα/IFNγ. Mean + S.E.M. of 3 independent experiments.
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NAMPT in tubular cells. However, the role of this stress-induced
NAMPT upregulation in tubular cell biology had not been previously
characterized.
Initial attempts to unravel the role of NAMPT on cultured renal cells
relied on the addition of exogenous NAMPT. Exogenous NAMPT induces0
1000
2000
3000
4000
β-Actin
TRAIL
*
TR
A
IL
 (%
 ov
er
 co
nt
ro
l)
Fig. 7. Inhibition of endogenousNAMPT further increases TNFα/IFNγ-induced TRAIL lethal
cytokine expression. Cells were cultured for 24 h with TNFα/IFNγ (50 ng/mL and
5 ng/mL). NAMPT enzymatic activity was inhibited with 10 nM FK866. Western blot of
cell lysates. β-Actin was used as loading control. Results expressed as mean + S.E.M. of
4 independent experiments. Representative Western blot. *p b 0.05 vs TNFα/IFNγ alone.production of proﬁbrotic molecules in rat mesangial cells and murine
podocytes and tubular epithelial cells [21,22]. Exogenous NAMPT also
increased MCP-1 expression in murine renal epithelial cells [22] and
synthesis of several renin angiotensin system components in cultured
rat mesangial cells [41]. Exogenous NAMPT increased the synthesis of
pro-ﬁbrotic molecules and MCP-1 through a cytochalasin-B sensitive
mechanism suggesting dependence on cellular glucose uptake [22].
These observations in kidney cells were consistent with data in other
cell systems. Thus, NAMPT activated the transcription factors NF-κB
and AP1 and induced cytokine synthesis in rheumatoid arthritis sy-
novial ﬁbroblasts and monocytes. In ﬁbroblasts NAMPT knockdown
inhibited basal and TLR ligand-induced production of cytokines
[40]. In contrast to the liver and the kidney, immune cells seem to
rely exclusively on the NAMPT salvage pathway for NAD biosynthesis
[42]. Thus, cells of the immune system express high levels of NAMPT
[43]. In immune cells FK866 decreased intracellular NAD and reduced
TNF-α synthesis in response to LPS [43]. However, cells displaying low
intracellular NAD levels retained the ability to secrete other proteins
(such as the chemokine RANTES) in response to the same stimuli.
Thus, the role of endogenous NAMPT on the synthesis of inﬂammatory
mediators is cell-type speciﬁc: endogenous NAMPTmay be required for
full activation of the inﬂammatory response in cells with constitutive
high NAMPT and NAD levels, such as immune cells.
In cultured mesangial cells exogenous NAMPT increased intracellu-
lar NAD concentrations and FK866 signiﬁcantly inhibited NAMPT-
induced NAD biosynthesis, suggesting NAMPT-mediated NAD biosyn-
thesis [21]. In addition, in mesangial cells FK866 decreased exogenous
NAMPT-induced glucose uptake, suggesting NAD involvement in
NAMPT-mediated glucose uptake. However, the effect of FK866 on cell
survival or inﬂammatory mediator synthesis was not explored. At
least some actions of exogenous NAMPT on vascular cells depend on
its enzymatic activity [31,44,45] and exogenous NAMPT enhanced
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that exogenous NAMPT did not modulate cell death or proliferation in
non-stressed human tubular cells.
Endogenous NAMPT may also regulate cell proliferation and cell
death. In endothelial cells NAMPT overexpression increased prolifera-
tion and extended replicative lifespan, preferentially during glucose
overload [46]. High intracellular NAD levels may act through sirtuins
to favor tumor cell survival, especially in response to genotoxic stress
[47]. Increased NAMPT activity is a physiological response to replenish
NAD levels in cells exposed to stress. Thus, by blocking this response,
FK866 decreased intracellular NAD and reduced proliferation and in-
duced apoptosis in human leukemia cell lines [48] and inhibited growth
of glioblastoma cells and other tumor cells [14,49,50]. This is the basis
for a potential role of NAMPT targeting on cancer therapy. Along the
same lines, the NAMPT inhibitor FK866 increased sensitivity to cell
death of mouse ﬁbroblasts exposed to genotoxic stress [13,51], demon-
strating that NAMPT regulation of cell viability requires its enzymatic
activity and that endogenous NAMPT may be cytoprotective under
conditions of cell stress. However there was no prior information on
the relationship between the enzymatic function of stress-induced
endogenous NAMPT and cell death or inﬂammatory responses in an
inﬂammatory milieu, as may be found in the kidney during DN. InTNFα
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Fig. 8.Hypothetical role of exogenous and endogenousNAMPT on kidney tubular epithelial cell
cells may be exposed to exogenous NAMPT, not originated in tubular cells, that may be derived
may be released locally frommacrophages. This manuscript conﬁrms the pro-inﬂammatory act
lications. In addition it provides evidence that cultured tubular cells express increased amounts
supernatants and as an intracellular protein in cell extracts. Evidence derived from siRNA targ
enzymatic activity suggests an anti-inﬂammatory, cell-protective role for endogenous NAMPT.
cellular versus intracellular endogenous NAMPT. The relative contribution of both sources of N
tubular epithelium, Potential explanations for the diverse roles of endogenous vs exogenous
by endogenous NAMPT; b) a potential protective role of different molecular forms of extracell
extracellular NAMPT. In this regard, NAMPT concentrations in renal cell supernatants have been
in tubular cells aremostmarkedwhen cells are stressed in an inﬂammatorymicroenvironment.
in response to inﬂammatory stress may help the cells to withstand that stress, while high amo
sence of stress.non-stressed tubular cells inhibition of NAMPT activity with FK866
slightly increased tubular cell proliferation, without modifying the
apoptosis rate. This should be interpreted in the context of FK866 as
an experimental anti-cancer drug. A potential extrapolation is that no
direct kidney toxicity might be expected in normal healthy kidneys
when using FK866 therapeutically for cancer. However, the conse-
quences of the therapeutic use of FK866 for the kidney may differ
under situations of kidney stress. Thus, tubular cells stressed with the
inﬂammatory cytokines TNFα and IFNγ became dependent on endoge-
nous NAMPT for survival and inhibition of endogenous NAMPT activity
increased cell death. The precise contributors to the increased cell death
observed were not speciﬁcally characterized. However, increased
expression of the lethal cytokine TRAIL was observed that coincided in
timewith the increased amount of cell death. TRAIL had beenpreviously
shown to promote death of tubular cells in an inﬂammatory environ-
ment [52]. Furthermore, under these culture conditions, inhibition of
endogenous NAMPT prolonged TNFα-induced chemokine expression
to 24 h. However, only a modest increase in total cell NAMPT was
observed at this time point. This observation may have two potential
explanations: a) that the trend to increased NAMPT observed at 24 h
of stimulation is already functionally signiﬁcant at 24 h or that the clear-
ly increased endogenous extracellular NAMPT contributed to the effect;Liver
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?
terstitial
xogenous 
NAMPT
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pathophysiology. During kidney injury tubular cell NAMPT is increased. In addition, kidney
from the circulation where both the liver and fat tissue are thought to be contributors, or
ion of exogenous, extracellular NAMPT over parenchymal cells described in previous pub-
of endogenous NAMPT that can be found both as an extracellular protein in the cell culture
eting of endogenous NAMPT and from pharmacological inhibition of endogenous NAMPT
The design of the experiments does not allow to independently explore the role of extra-
AMPT should be addressed in vivo, for example, by selectively knocking down NAMPT in
NAMPT include: a) a key contribution of intracellular NAMPT to the observed protection
ular NAMPT produced by tubular cells; and c) a hypothetical role for the concentration of
reported to be low. The anti-inﬂammatory and cell-protective endogenousNAMPT effects
Thus, intracellular NAMPT or low amounts of endogenousNAMPT released by tubular cells
unts of exogenously added extracellular NAMPT may be detrimental, especially in the ab-
302 A. Benito-Martin et al. / Biochimica et Biophysica Acta 1842 (2014) 293–303and b) as an alternative, that another unidentiﬁed regulator might be
responsible for the observation.
5. Conclusion
How do we reconcile the proinﬂammatory role of exogenous
NAMPT with the anti-inﬂammatory, cell-protective role of endogenous
NAMPT in tubular cells in an inﬂammatory milieu? Any interpretation
must take into account two facts: a) the concentration of exogenous
NAMPT that promotes proﬁbrotic and inﬂammatory responses in
renal cells is in the 10–100 ng/mL range, as observed in this paper and
by other authors [22]. This is the concentration range reported for circu-
lating visfatin/NAMPT in CKD patients [38]. By contrast, extracellular
NAMPT released by renal cells is measured in pg, a 1000-fold lower
concentration [21,22]. We have now conﬁrmed secretion of NAMPT
by tubular cells, consistent with previous ﬁndings. Thus we are unable
to pinpoint the protective effect of endogenous NAMPT to the fact that
it is the intracellular form. We cannot discard that besides any differ-
ence in concentration; posttranslational modiﬁcations of renal cell
NAMPT explain these differential properties of endogenous NAMPT be
it intracellular or secreted. b) The proinﬂammatory action of exogenous
NAMPT has been observed in non-stressed cells, as exempliﬁed by
data presented here and by others [21,22,53] However, the anti-
inﬂammatory and cell-protective endogenous NAMPT effects in tubular
cells are observed when cells are stressed in an inﬂammatory microen-
vironment. Thus, our current interpretation is that low amounts of
endogenous NAMPT synthesized by tubular cells in response to inﬂam-
matory stress help the cells towithstand that stress,while high amounts
of exogenously added NAMPT may be detrimental, especially in the
absence of stress. Our data and experimental design do not allow to
discriminate between effects of endogenous, intracellular NAMPT ver-
sus endogenous extracellular (that is, NAMPT secreted by the tubular
cells) NAMPT (Fig. 8). Both siRNA and inhibitor experiments suggest a
protective role of NAMPT synthesized by tubular cells in a pro-
inﬂammatory milieu. In addition when NAMPT was targeted by siRNA
the results also suggest a protective role in the absence of an inﬂamma-
tory milieu. We hypothesize that this may be related to the cell stress
resulting from siRNA transfection that acts a surrogate for cell stress
resulting from inﬂammatory cytokine exposure.
In summary, we have uncovered an anti-inﬂammatory, cell-
protective role of endogenous NAMPT in tubular cells cultured under
stress conditions with features of the DN milieu. This information will
be useful to study NAMPT as a potential therapeutic target in kidney
injury. In addition it raises a note of caution regarding the potential
nephrotoxicity of the use of NAMPT inhibitors in other ﬁelds of
Medicine, such as Oncology, when prescribed to patients with DN
[54]. Taking into account the multifunctional nature of NAMPT, the
ﬁnal in vivo result of the therapeutic modulation of NAMPT on kidney
injury has to be addressed in experimental animal models that discrim-
inate between tubular and non-tubular sources of NAMPT, such as
selective knock-down of NAMPT in tubular epithelium.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2013.11.022.
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